Rapid identification of Burkholderia cepacia complex species recovered from cystic fibrosis patients using matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

The aim of this study was to establish the identification ability of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) for bacteria of Burkholderia cepacia complex (Bcc) and to compare these results with those obtained by a molecular method (PCR-RFLP). A total of 57 isolates was used in the study. Isolates were collected from 31 patients attending the Regional Cystic Fibrosis Unit from January 2001 to December 2005. For phenotypic identification, both automated and manual systems were used. Using mass spectrometry, we identified all 57 isolates, previously identified by molecular method. Of these, 28 isolates were identified as B. cenocepacia, although not differentiated further into lineages. Moreover, other isolates were identified as B. cepacia (12 isolates), B. stabilis (12 isolates), and B. vietnamiensis (5 isolates). Our data indicate a good correlation between the two approaches.

[1]  P. Vandamme,et al.  Proposal to accommodate Burkholderia cepacia genomovar VI as Burkholderia dolosa sp. nov. , 2004, International journal of systematic and evolutionary microbiology.

[2]  P. Dawyndt,et al.  Matrix-assisted laser desorption ionisation-time-of of-flight mass spectrometry of intact cells allows rapid identification of Burkholderia cepacia complex. , 2008, Journal of microbiological methods.

[3]  J. Elborn,et al.  PCR-Based Detection and Identification ofBurkholderiacepacia Complex Pathogens in Sputum from Cystic Fibrosis Patients , 2001, Journal of Clinical Microbiology.

[4]  T. Mott,et al.  Identification of Potential Diagnostic Markers among Burkholderia cenocepacia and B. multivorans Supernatants , 2010, Journal of Clinical Microbiology.

[5]  M. Kaufmann,et al.  Distribution of Genes Encoding Putative Transmissibility Factors among Epidemic and Nonepidemic Strains ofBurkholderia cepacia from Cystic Fibrosis Patients in the United Kingdom , 2000, Journal of Clinical Microbiology.

[6]  M. Barchitta,et al.  Burkholderia cepacia Complex Infection in Italian Patients with Cystic Fibrosis: Prevalence, Epidemiology, and Genomovar Status , 2001, Journal of Clinical Microbiology.

[7]  L. Saiman,et al.  Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. , 2003, American journal of infection control.

[8]  J. Lipuma,et al.  Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis. , 2003, FEMS microbiology letters.

[9]  Tom Coenye,et al.  Burkholderia cenocepacia sp. nov.--a new twist to an old story. , 2003, Research in microbiology.

[10]  P. Lasch,et al.  Rapid identification of Burkholderia cepacia complex species including strains of the novel Taxon K, recovered from cystic fibrosis patients by intact cell MALDI-ToF mass spectrometry. , 2009, The Analyst.

[11]  Albert Balows,et al.  Manual of Clinical Microbiology, 7th ed. , 2000 .

[12]  P. Vandamme,et al.  Characterization of Unusual Bacteria Isolated from Respiratory Secretions of Cystic Fibrosis Patients and Description of Inquilinus limosus gen. nov., sp. nov , 2002, Journal of Clinical Microbiology.

[13]  P. Dřevínek,et al.  Direct PCR Detection of Burkholderia cepacia Complex and Identification of Its Genomovars by Using Sputum as Source of DNA , 2002, Journal of Clinical Microbiology.

[14]  B. Tümmler,et al.  A physical genome map of the Burkholderia cepacia type strain , 1995, Molecular microbiology.

[15]  R. Cole,et al.  Rapid identification and speciation of Haemophilus bacteria by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 1998, Journal of mass spectrometry : JMS.

[16]  K. Voorhees,et al.  Identification of bacterial proteins observed in MALDI TOF mass spectra from whole cells. , 1999, Analytical chemistry.

[17]  V. Raia,et al.  Burkholderia cepacia complex infection in a cohort of Italian patients with cystic fibrosis. , 2007, Journal of microbiology.

[18]  P. Vandamme,et al.  Identification of species of the Burkholderia cepacia complex by sequence analysis of the hisA gene. , 2010, Journal of medical microbiology.

[19]  P. Berche,et al.  Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Nonfermenting Gram-Negative Bacilli Isolated from Cystic Fibrosis Patients , 2008, Journal of Clinical Microbiology.

[20]  H. Fang,et al.  Evaluation of species-specific PCR, Bruker MS, VITEK MS and the VITEK 2 system for the identification of clinical Enterococcus isolates , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[21]  C. Hart,et al.  Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia , 1998, Thorax.

[22]  V. Raia,et al.  BMC Infectious Diseases BioMed Central Research article , 2006 .

[23]  Andrew T. Lloyd,et al.  Evolution of the recA gene and the molecular phylogeny of bacteria , 1993, Journal of Molecular Evolution.

[24]  M. Dodd,et al.  Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis , 2004, Thorax.

[25]  C. Fenselau,et al.  Characterization of the protein subset desorbed by MALDI from whole bacterial cells. , 2001, Analytical Chemistry.

[26]  P. Vandamme,et al.  Phenotypic Methods for Determining Genomovar Status of the Burkholderia cepacia Complex , 2001, Journal of Clinical Microbiology.

[27]  V. Raia,et al.  Sphingobacterium respiratory tract infection in patients with cystic fibrosis , 2009, BMC Research Notes.

[28]  J. Lipuma,et al.  BURKHOLDERIA CEPACIA: Management Issues and New Insights , 1998 .

[29]  V. Raia,et al.  Chryseobacterium respiratory tract infections in patients with cystic fibrosis. , 2007, The Journal of infection.

[30]  P. Vandamme,et al.  Burkholderia anthina sp. nov. and Burkholderia pyrrocinia, two additional Burkholderia cepacia complex bacteria, may confound results of new molecular diagnostic tools. , 2002, FEMS immunology and medical microbiology.

[31]  R. Fani,et al.  Application of multiplex single nucleotide primer extension (mSNuPE) to the identification of bacteria: the Burkholderia cepacia complex case. , 2010, Journal of microbiological methods.

[32]  S. N. Davey,et al.  The rapid identification of intact microorganisms using mass spectrometry , 1996, Nature Biotechnology.

[33]  David J Weber,et al.  Infection control in cystic fibrosis: practical recommendations for the hospital, clinic, and social settings. , 2000, American journal of infection control.

[34]  D. Peckham,et al.  Alcaligenes infection in cystic fibrosis , 2002, Pediatric pulmonology.

[35]  Y. Kawamura,et al.  Evaluation of a Simple Protein Extraction Method for Species Identification of Clinically Relevant Staphylococci by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry , 2012, Journal of Clinical Microbiology.

[36]  P. Vandamme,et al.  DNA-Based Diagnostic Approaches for Identification of Burkholderia cepacia Complex, Burkholderia vietnamiensis, Burkholderia multivorans,Burkholderia stabilis, and Burkholderia cepacia Genomovars I and III , 2000, Journal of Clinical Microbiology.

[37]  L. Saiman,et al.  Identification and Antimicrobial Susceptibility ofAlcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis , 2001, Journal of Clinical Microbiology.

[38]  D. Simpson,et al.  Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis , 1997, Journal of clinical microbiology.